• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Biodexa Pharmaceuticals plc American Depositary Shs

    7/23/24 3:09:44 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BDRX alert in real time by email
    SC 13G 1 ea0209895-13gbrio_biodexa.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934*

     

    BIODEXA PHARMACEUTICALS PLC
    (Name of Issuer)
     
    AMERICAN DEPOSITORY SHARES**
    (Title of Class of Securities)
     
    59564R708***
    (CUSIP Number)
     
    July 15, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐   Rule 13d-1(b)

    ☒   Rule 13d-1(c)

    ☐   Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    **Each American Depository Share represents 400 ordinary shares, nominal value £0.001 per share, of the Issuer.

     

    ***The CUSIP number applies to the American Depositary Shares of the Issuer.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No.   59564R708

     

    1.

    Names of Reporting Persons

     

    Brio Capital Master Fund Ltd.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)   ☐

    (b)   ☐

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    Cayman Islands

    Number of Shares

    Beneficially Owned

    By Each Reporting

    Person With:

    5.

    Sole Voting Power

     

    1,427,861 American Depository Shares(1) (2)

    6.

    Shared Voting Power

     

    0

    7.

    Sole Dispositive Power

     

    1,427,861 American Depository Shares(1) (2)

    8.

    Shared Dispositive Power

     

    0

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,427,861 American Depository Shares(1) (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☒

     

    See footnote (2) below. (See Instructions)

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.83%(3)

    12.

    Type of Reporting Person (See Instructions)

     

    CO

     

    (1)Brio Capital Management LLC, is the investment manager of Brio Capital Master Fund Ltd. and has the voting and investment discretion over securities held by Brio Capital Master Fund Ltd. Shaye Hirsch, in his capacity as Managing Member of Brio Capital Management LLC, makes voting and investment decisions on behalf of Brio Capital Management LLC in its capacity as the investment manager of Brio Capital Master Fund Ltd.

     

    (2)This amount excludes American Depository Shares issuable upon exercise of the Warrants since each of these Warrants is not exercisable when holder beneficially owns in excess of 4.99% of the outstanding shares.

     

    (3)Percentage calculation is based on the number of ordinary shares outstanding as of July 23, 2024, as reported on the company’s website.

     

    2

     

     

    CUSIP No.   59564R708

     

    1.

    Names of Reporting Persons

     

    Brio Capital Management LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)   ☐

    (b)   ☐

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware, United States

    Number of Shares

    Beneficially Owned

    By Each Reporting

    Person With:

    5.

    Sole Voting Power

     

    1,427,861 American Depository Shares (4)(5)

    6.

    Shared Voting Power

     

    0

    7.

    Sole Dispositive Power

     

    1,427,861 American Depository Shares (4)(5)

    8.

    Shared Dispositive Power

     

    0

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,427,861 American Depository Shares (4)(5)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☒

     

    See footnote (5) below. (See Instructions) 

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.83%(6)

    12.

    Type of Reporting Person (See Instructions)

     

    CO

     

    (4)Brio Capital Management LLC, is the investment manager of Brio Capital Master Fund Ltd. and has the voting and investment discretion over securities held by Brio Capital Master Fund Ltd. Shaye Hirsch, in his capacity as Managing Member of Brio Capital Management LLC, makes voting and investment decisions on behalf of Brio Capital Management LLC in its capacity as the investment manager of Brio Capital Master Fund Ltd.

     

    (5)This amount excludes American Depository Shares issuable upon exercise of the Warrants since each of these Warrants is not exercisable when holder beneficially owns in excess of 4.99% of the outstanding shares.

     

    (6)Percentage calculation is based on the number of ordinary shares outstanding as of July 23, 2024, as reported on the company’s website.

     

    3

     

     

    Item 1(a). Name of Issuer
       
      Biodexa Pharmaceuticals PLC (the “Issuer”)
       
    Item 1(b). Address of the Issuer’s Principal Executive Offices
       
     

    1 Caspian Point, Caspian Way

    Cardiff, CF10 4DQ, United Kingdom.

       
    Item 2(a). Names of Persons Filing

     

    This Schedule 13G is filed jointly by:

     

      Brio Capital Master Fund Ltd.
      Brio Capital Management LLC

     

    The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.” Information with respect to each Reporting Person is given solely by such Reporting Person, and no Reporting Person assumes responsibility for the accuracy or completeness of the information furnished by another Reporting Person.

     

    Each Reporting Person expressly declares that neither the filing of this statement nor anything herein shall be construed as an admission that such Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

     

    Item 2(b). Address of the Principal Business Office, or if none, Residence:
       
      c/o Brio Capital Management LLC, 100 Merrick Road, Suite 401 W. Rockville Center, NY 11570.
       
    Item 2(c). Citizenship

     

     

    Brio Capital Master Fund Ltd. – Cayman Islands

    Brio Capital Management LLC – United States

     

    Item 2(d). Title of Class of Securities
       
     

    American Depository Shares. Each American Depository Share represents 400 ordinary shares, nominal value £0.001 per share, of the Issuer.

       
    Item 2(e). CUSIP Number
       
      59564R708
       
    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

      

      ¨ (a)  Broker or Dealer registered under Section 15 of the Exchange Act.
         
      ¨ (b) Bank as defined in Section 3(a)(b) or the Exchange Act.
         
      ¨ (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act.
         
      ¨ (d) Investment company registered under Section 8 of the Investment Company Act.

     

      ¨ (e) An Investment adviser in accordance with Rule 13d-1 (b)(1)(ii)(e).
         
      ¨ (f)  An employee benefit plan or endowment fund in accordance with Rule 13d 1(b)(1)(ii)(f).
         
      ¨ (g) A Parent Holding Company or control person in accordance with Rule 13d 1(b)(1)(ii)(g).
         
      ¨ (h) A Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act.
         
      ¨

    (i) A Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.

         
      ¨ (j) Group, in accordance with Rule 13d-1 (b)(1)(ii)(j).
         
        Not applicable

     

    4

     

     

    Item 4.

    Ownership

     

    The information required by Items 4(a)-(c) is set forth in Rows 5-11 of each Cover Page and is incorporated herein by reference.

     

    Each Reporting Person expressly declares that neither the filing of this statement nor anything herein shall be construed as an admission that such Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      Not Applicable
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not Applicable 
       
    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

       
      Not Applicable
       
    Item 8. Identification and Classification of Members of the Group
       
      Not Applicable
       
    Item 9. Notice of Dissolution of Group
       
      Not Applicable
       
    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    5

     

     

    LIST OF EXHIBITS

     

    Exhibit No.   Description
         
    Exhibit 1   Joint Filing Agreement

       

     

    6

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    DATE:   July 23, 2024

     

      Brio Capital Master Fund Ltd.,
      a Cayman Islands Exempted Company
         
      By: Brio Capital Management LLC, its Investment Manager
         
      By: /s/ Shaye Hirsch
        Name:   Shaye Hirsch
        Title: Managing Member
         
      Brio Capital Management LLC,
      a Delaware limited liability company
         
      By: /s/ Shaye Hirsch
        Name: Shaye Hirsch
        Title: Managing Member

     

    Attention:  Intentional misstatements or omissions of fact constitute Federal criminal violations

    (See 18 U.S.C. 1001)

      

    7

     

    Get the next $BDRX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BDRX

    DatePrice TargetRatingAnalyst
    2/8/2024$8.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $BDRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ADR Ratio Change

      July 15, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") ADR Ratio Change Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces a ratio change on its American Depositary Receipts ("ADR") from one (1) ADR representing ten thousand (10,000) ordinary shares, to the new ratio of one (1) ADR representing one hundred thousand (100,000) ordinary shares (the "Ratio Change"). The effective date of the Ratio Change is expected to be July 31, 2025. Pursuant to the Ratio Change, ADR holders will be required on a mandato

      7/15/25 4:30:00 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

      July 14, 2025 Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced the filing of a Clinical Trial Application (CTA) with the European Medicines Agency (EMA) for its Serenta trial in patients with familial adenomatous polyposis (FAP), a mostly inherited disease that, if left untreated, almost always leads to colorectal cancer. The only current treatment option is sequential resection of much of the gastrointesti

      7/14/25 8:30:00 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Results of Annual General Meeting

      June 27, 2023 Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Results of Annual General Meeting Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces that at its Annual General Meeting held yesterday, all resolutions put to the Company's shareholders were duly passed. The full text of, inter alia, the resolutions proposed and passed at the Annual General Meeting can be found in the Notice of the Annual General Meeting on the Company's website at https://biodexapharma.com/investors/corporate-governance//#agms. About Biodexa Pharmaceutica

      6/27/25 8:30:00 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDRX
    SEC Filings

    See more
    • SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

      424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      7/18/25 5:23:50 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

      424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      7/18/25 5:23:11 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

      424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      7/18/25 5:23:01 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ladenburg Thalmann initiated coverage on Biodexa Pharmaceuticals PLC with a new price target

      Ladenburg Thalmann initiated coverage of Biodexa Pharmaceuticals PLC with a rating of Buy and set a new price target of $8.00

      2/8/24 7:21:49 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

      March 6, 2025 Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP Biodexa is finalizing plans to initiate an international Phase 3 registrational study of eRapa in Familial Adenomatous Polyposis (FAP) next quarter Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the appointment of Precision for Medicine, LLC ("Precision") as the clinical research organization ("CRO") to conduct the European component of the upcoming registrational Phase 3

      3/6/25 8:30:00 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

      January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announced today the appointment of Dr Gary A. Shangold as Chief Medical Officer with immediate effect. Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "I am delighted to welcome Gary to the team. As Biodexa moves towards the later clinical stages including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists

      1/22/25 8:30:00 AM ET
      $BDRX
      $JNJ
      $SWKH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Diversified Financial Services
      Finance
    • Biodexa Appoints Ann Merchant to the Board of Directors

      Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Biodexa Appoints Ann Merchant to the Board of Directors CARDIFF, United Kingdom, Dec. 29, 2023 (GLOBE NEWSWIRE) – Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs including Type 1 diabetes and rare / orphan brain cancers, is pleased to announce the appointment of Ann Merchant to the Board of Directors of the Company as Non-executive Director with effect from 31 December 2023. Since 2018, Ann Merchant has served as Vice President for MorphoSys, and currently as Head of Global Supply Chain and Externa

      12/29/23 4:05:00 AM ET
      $ALVO
      $BDRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $BDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

      SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      11/20/24 11:56:39 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

      SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      11/14/24 5:12:47 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

      SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      11/12/24 4:30:48 PM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDRX
    Financials

    Live finance-specific insights

    See more
    • Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

      CARDIFF, UK / ACCESSWIRE / November 21, 2024 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs, has made significant progress in transforming itself from a drug delivery innovator to a therapeutics company with a focus on drugs to fight diabetes and cancer. Biodexa's strategy is not based on discovering new medicines; rather it looks to reduce the risk of failure in the clinic by re-purposing molecules with proven safety records for new indications. When Biodexa sees potential, it acquires these products from third parties under licensing agreements which generally call

      11/21/24 7:35:00 AM ET
      $BDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care